title: The p.Val66Met polymorphism in the BDNF gene protects against early seizures in Rett syndrome.
abstract: OBJECTIVE
  X chromosome inactivation and the MECP2 genotype do not provide the full explanations for the clinical differences between patients with Rett syndrome (RTT), suggesting the involvement of other factors. One MeCP2 target is the brain-derived neurotrophic factor (BDNF) gene. We investigated, according to the MECP2 genotype, the role of the BDNF functional polymorphism (Val66Met) on the severity of RTT.
  
  
  METHODS
  This polymorphism in BDNF was analyzed by PCR and dHPLC in 81 patients with RTT. We studied the association between the MECP2 and BDNF genotypes and the clinical features in each patient.
  
  
  RESULTS
  We found that some RTT features can be correlated with MECP2 genotypes. Missense mutations are associated with a more severe epileptic phenotype (early onset and drug resistance) than other mutations. Non-sense and late truncating mutations lead to a less severe phenotype regarding walking. The distribution of the Val66Met polymorphism was not significantly different between the different groups in regard to the severity of all tested symptoms. However, girls with RTT bearing the Val66Val genotype tend to present earlier seizures than girls with RTT bearing the Met66 allele. No girls with RTT with the Met66 allele presented early seizures.
  
  
  CONCLUSIONS
  Early onset of seizures is linked to the combined MECP2 and BDNF genotypes. The BDNF Met66 allele may protect against seizures, whereas missense mutations in the MBD of MECP2 are more frequently associated with early seizures.
authors.affiliation: Laboratoire de Biochimie et Genetique Moleculaire, Hopital Cochin, Paris, France.
authors.forename: J
authors.initials: J
authors.lastname: Nectoux
authors.forename: N
authors.initials: N
authors.lastname: Bahi-Buisson
authors.forename: I
authors.initials: I
authors.lastname: Guellec
authors.forename: J
authors.initials: J
authors.lastname: Coste
authors.forename: N
authors.initials: N
authors.lastname: De Roux
authors.forename: H
authors.initials: H
authors.lastname: Rosas
authors.forename: M
authors.initials: M
authors.lastname: Tardieu
authors.forename: J
authors.initials: J
authors.lastname: Chelly
authors.forename: T
authors.initials: T
authors.lastname: Bienvenu
mesh_terms: D000293:Adolescent; D000328:Adult; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics*; D002648:Child; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008715:Methionine / Q000235:genetics*; D051783:Methyl-CpG-Binding Protein 2 / Q000235:genetics; D010641:Phenotype; D011110:Polymorphism, Genetic / Q000235:genetics*; D015518:Rett Syndrome / Q000150:complications / Q000235:genetics*; D012640:Seizures / Q000209:etiology / Q000235:genetics*; D014633:Valine / Q000235:genetics*
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D051783:Methyl-CpG-Binding Protein 2; D008715:Methionine; D014633:Valine